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Background: Alzheimer’s disease (AD) is the most common type of dementia affecting people over 65 years of
age. The hallmarks of AD are the extracellular deposits known as amyloid β plaques and the intracellular
neurofibrillary tangles, both of which are the principal players involved in synaptic loss and neuronal cell death. Tau
protein and Aβ fragment 1–42 have been investigated so far in cerebrospinal fluid as a potential AD biomarkers.
However, an urgent need to identify novel biomarkers which will capture disease in the early stages and with
better specificity remains. High-throughput proteomic and pathway analysis of hippocampal tissue provides a
valuable source of disease-related proteins and biomarker candidates, since it represents one of the earliest affected
brain regions in AD.
Results: In this study 2954 proteins were identified (with at least 2 peptides for 1203 proteins) from both control
and AD brain tissues. Overall, 204 proteins were exclusively detected in AD and 600 proteins in control samples.
Comparing AD and control exclusive proteins with cerebrospinal fluid (CSF) literature-based proteome, 40 out of
204 AD related proteins and 106 out of 600 control related proteins were also present in CSF. As most of these
proteins were extracellular/secretory origin, we consider them as a potential source of candidate biomarkers that
need to be further studied and verified in CSF samples.
Conclusions: Our semiquantitative proteomic analysis provides one of the largest human hippocampal proteome
databases. The lists of AD and control related proteins represent a panel of proteins potentially involved in AD
pathogenesis and could also serve as prospective AD diagnostic biomarkers.
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Alzheimer’s disease (AD) is a progressive neurodegener-
ative disease mainly affecting people over the age 65.
The hallmarks of AD are the extracellular deposits
known as amyloid β (Aβ) plaques and the intracellular
neurofibrillary tangles (NFT), the principal players
thought to be involved in synaptic loss and neuronal cell
death [1,2]. Currently, diagnosis of AD is based on* Correspondence: ediamandis@mtsinai.on.ca
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reproduction in any medium, provided the orclinical criteria that are relied on neuropsychological
examination, mental status testing and insight into the
medical history of the patients. However, still, the gold
standard for AD diagnosis remains histological examin-
ation of post mortem brain regions. Furthermore, there
are no accurate methods to track the efficacy of new
therapies. Hence, there is a desperate need for specific
biomarkers that proactively identify evolving cases of
AD and may lend way to more favorable medical out-
comes [3]. Cerebrospinal fluid (CSF) has been so far the
most promising source of potential protein biomarkers.
CSF amyloid β 1–42 fragment (Aβ 1–42) has shown
about 50% decrease in AD patients in comparison to
cognitively normal individuals [4,5], however it is notal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and













Figure 1 Overlap of the identified proteins in Alzheimer’s
disease (AD), control samples and CSF proteome. (A) Overlap of
the proteins identified in post-mortem hippocampal tissue
specimens from AD patients and age-matched healthy controls. AD
and control pools (n = 3) were analysed in triplicates. (B) Overlap of
AD and control proteins with literature-based CSF proteome [23].
The comparison reveals that 40 AD-specific proteins identified in the
current study were also present in the CSF database.
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dementia [6]. Other prospective candidates, total tau
(T-tau) and phosphorylated tau (P-tau) levels have been
found increased in CSF AD cases compared to controls
[7]. Although T-tau levels have a trend to be elevated in
other neurodegenerative diseases as well [8], indicating
the lack of specificity, P-tau levels may discriminate AD
from other types of dementias [9,10]. The combination
of these three biomarkers represents markers for Aβ
depositions as well as neuronal injury and have con-
firmed good diagnostic accuracy in early AD by multi-
center studies in CSF [10]. In addition, measurement of
Aβ 1–42, T-tau and P-tau levels in CSF are included in
the diagnostic criteria for diagnosis of mild cognitive im-
pairment due to AD [11]. Human brain tissue proteo-
mics have been studied gradually in the last decade
[12-14]. A recent proteomic study with mass spectrom-
etry analysis has demonstrated a total of 197 proteins
differentially abundant in AD versus controls, after
examining the temporal lobe region [15], whereas in an-
other study 18 proteins were identified in hippocampus
region with altered protein level that are involved in dif-
ferent cellular functions in AD pathology [16]. Together
with temporal lobe, hippocampus is one of the earliest
affected regions in AD pathology, when memory and
cognitive functions are already impaired [17,18]. There-
fore, proteomic analysis of AD hippocampus, combined
with pathway analysis, could help in defining the eti-
ology of the disease as well as identify potential bio-
markers and therapeutic targets. We present here one of
the first comprehensive proteomic analyses of the hippo-
campal region of three brains affected by AD and three
age-matched controls.
Results and discussion
From the proteomic analysis of 6 hippocampal tissue
specimens (pool of 3 AD and pool of 3 controls), 2954
proteins were identified, with at least two peptides for
1203 of them. A total of 2354 proteins were detected
in AD tissues and 2750 in control tissues, with 204
proteins exclusively detected in AD and 600 in controls
(Figure 1A, Additional file 1). Furthermore, 1605 pro-
teins were identified in all the three AD technical repli-
cates, and 1755 proteins were identified in all the three
control technical replicates. Of 204 AD-exclusive pro-
teins, 124 were identified with ≥2 peptides. Two hun-
dred fifty five proteins in 600 control-exclusive proteins
were identified with ≥2 peptide hits. Analysis of tech-
nical and biological replicates is necessary to ensure the
accuracy and biological significance of proteomic
datasets. Pooling of biological replicates does not allow
statistical comparisons, but produces sufficient sample
to enhance the detection of low-abundance proteins
through technical replicates and helps to balance thebetween subject variability. In the current study, we
pooled biological replicates and performed SCX fraction-
ation of each pool in triplicate. A total of 120 fractions
were analysed with approximately 300 hours of instru-
ment time. An ideal proteomic study includes both bio-
logical and technical replicates. With this study, we
intended to generate a comprehensive hippocampal
proteome dataset and build a platform for future transla-
tional investigations in AD. Therefore, we pooled our
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included technical triplicates to enhance confidence in
protein identification and increase the depth of prote-
omic analysis. Despite the shortcomings of our pooling
strategy, our study unveiled the largest hippocampal
proteome database reported to date. We believe that the
proteome presented here provides a valuable resource
for researchers aiming to develop novel AD biomarkers
and therapeutic targets. Post-mortem interval (PMI) is a
critical factor affecting integrity of the proteome in post-
mortem tissues. A short PMI (<2 h) is advantageous in
proteomics studies of human tissues, since PMI-prone
artifacts, such as proteolytic degradation, insolubility
and oxidation/nitration of certain proteins, are mini-
mized and results more likely represent the intrinsic
situation in AD and control brains. However, due to
scarcity of post-mortem tissues, it is not always possible
to secure tissues with short PMIs. In the current study,
2 of 6 tissues have a PMI of < 4 h and the rest were
collected at ~12 h PMI. A recent study using
2-dimenstional gel electrophoresis (2DE) showed that
only a small percentage (6.5% of ~2500 proteins) of
brain proteins underwent proteolytic degradation after
48 h PMI with no significant changes in their solubility
[19]. Techniques such as 2DE and western blots could
only capture intact proteins, leaving out proteolytic pep-
tides, and this severely impacts the quality of proteomic
analysis. On the other hand, sample preparation
methods used in the current study, e.g. strong cation ex-
change chromatography, will ensure the capture of total
proteome that includes proteolytically degraded peptides
as well as trypsin-generated peptides. In addition, we
also avoided the dialysis procedure to prevent loss of
low molecular weight proteolytic peptides. Therefore,
the overall effect of proteolytic degradation during PMI
is minimized.
It should be noted that when the same amount of total
protein was processed for proteomic analysis; more pro-
teins were identified in controls, compared to AD tis-
sues. Lower number of protein identifications in AD
tissues may be attributed to inherent insolubility of pro-
tein aggregates which renders them inaccessible to tryp-
sin proteolytic activity. To the best of our knowledge,
the current report presents the largest hippocampal
proteome dataset published to date. Moesin (MSN), heat
shock protein beta-1 (HSPB1), S100B protein (S100B),
and chloride intracellular channel protein 1 (CLIC1)
were the top four over-expressed proteins (≥ 4.5-fold
measured in terms of spectral counts) in AD tissues.
Elongation factor 1-alpha 2 (EEF1A2), 2-oxoglutarate de-
hydrogenase (OGDH), isoform 1 of immunoglobulin
superfamily member 8 (IGSF8) and actin-related protein
2 (ACTR2) are highly down-regulated proteins (≥ 4.5-
fold) in AD tissues. Top 150 highly over-expressed andunder-expressed protein fold changes are presented as
additional information.
We relied upon “Protein Center” (Thermo Fisher Sci-
entific, USA) to retrieve Gene Ontology information for
cellular localization, biological processes and molecular
function of AD proteins. As expected, majority of identi-
fied proteins were of membranous and cytoplasmic ori-
gin and were associated with metabolic processes,
protein binding and catalytic functions (Figure 2). Pro-
teins identified in AD pool were compared against the
human proteome database to identify statistically signifi-
cant over-represented gene ontology functions using
BinGO (Cytoscape plugin) enrichment map. A p-value
threshold of <0.001 and a false discovery rate of FDR <
5% were used to confidently predict enriched GO terms
among AD proteins. Protein binding (p = 3.28E-82),
catalytic activity (p = 8.72E-37), oxido-reductase activity
(p = 7.78E-25), adenyl nucleotide binding (p = 1.10E-9),
SNARE binding (4.56E-8) and syntaxin binding (1.5E-6)
were the most significantly enriched molecular functions
of AD proteins. Among the biological processes, cellular
metabolic processes (p = 1.05E-42), primary metabolic
process (p = 8.21E-23), vesicle mediated transport (p =
1.16E-23), cellular ketone metabolic process (p = 3.08E-
21), oxidative phosphorylation (1.01E-17) and positive
regulation of ubiquitin activity (p = 3.15E-9) were of high
statistical significance. We employed “Protein center”
pathway analysis tools to explore the plausible patho-
logical relevance of differential expression (calculated by
spectral counting) of hippocampal proteins between AD
and Control groups. A total of 55 canonical pathways
were identified as over-represented due to this differen-
tial expression. Parkinson’s disease (p = 9.10E-10),
Alzheimer’s disease (p = 2.07E-7), synaptic vesicle cycle
(p = 0.001) and long term depression (p = 0.01) were of
considerable relevance to AD etiology. Figure 3 presents
KEGG AD pathway (hsa05010) [20] with the up-
regulated proteins marked in red and down-regulated
marked in green. Fifty four of 157 proteins involved in
this pathway were detected in this study (see Additional
file 2). These proteins were associated with critical
pathological aspects of AD; proteolytic processing of
amyloid precursor protein (APP), down-regulation of
oxidative phosphorylation, mitochondrial dysfunction,
calcium dysfunction and Aβ aggregation. Recent re-
search suggests that dysregulation of calcium homeosta-
sis in aged brains aberrantly activates calpains (cysteine
proteases), which, in turn, initiate the proteolytic degrad-
ation of key neuronal proteins, resulting in poor synaptic
transmission and memory loss [21,22]. Additionally,
calpains mediate the activation of extracellular signal-
regulated kinase ½ (ERK1/2), which induces hyper
phosphorylation of cytoskeletal proteins, including tau,
triggering a cascade of cellular events leading to the





Figure 2 Gene Ontology (GO) analysis. Diagram showing cellular localization (A), biological processes (B) and molecular mechanism (C) for AD
hippocampal proteome. Gene Ontology information was retrieved from ‘Protein center’ database.
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(CAPN1 and 2) and ERK1/2 in the current study coin-
cides with the aforementioned literature findings [22].
The underlying objective of the current study was to
segregate promising candidate biomarkers from the list
of 2954 proteins for future verification studies. To this
end, we considered the 204 and 600 proteins that were
identified exclusive to AD tissues and control tissues, re-
spectively. The failure to detect these proteins does not
endorse their absence; however, it does imply that these
proteins are differentially expressed. Mere differential
expression of a protein in AD tissues does not qualify
the protein to be a biomarker, unless its disease-specific
higher expression in tissues is reflected in easily access-
ible bio-fluids such as CSF or serum. In this light, we
compared the current hippocampal proteome with
literature-based CSF proteome [23]; 25% of 2954 tissue
proteins were present in CSF (see Additional file 1). A
considerable finding is that 40 of the 204 AD-exclusive
proteins and 106 of 600 control-exclusive proteins were
also detected in CSF (Figure 1B). Secretory origin is one
of the most important qualifications of biomarker candi-
date [24]. It is well-established that majority of CSF and
serum proteins are of extracellular and secretory origin.
Therefore, we assume that extracellular and secreted
proteins, identified in CSF and up/down-regulated in
AD tissues are favourable candidates for biomarker veri-
fication. As most of the 40 and 106 proteins that are
present in CSF proteome were either extracellular/secretory or membranous origin, therefore, it is worth-
while to include these proteins as a potential source of
candidate biomarkers that need to be further studied
and verified in CSF samples (please see Additional files 3
and 4). Please see Additional files 5 and 6 for differen-
tially-expressed proteins in AD and Control tissue pools.Conclusion
Hippocampus is one of the primary regions of the brain
affected by Alzheimer’s disease. This structure is known
to host tangles and plaques in the earliest phases of the
disease cascade, even before the appearance of clinical
symptoms. The proteome of such a pivotal region repre-
sent a promising source of diagnostic markers and mo-
lecular targets for therapeutic intervention. Herein, we
performed proteomic analysis of freshly-frozen post-
mortem hippocampal tissue sections from Alzheimer’s
patients (n = 3) and age-matched controls (n = 3). Our
detailed proteomic analysis utilizing offline multidimen-
sional chromatography coupled with the LTQ-Orbitrap
XL mass spectrometer and semiquantitative spectral
counting methods identified 2954 proteins, one of the
largest human hippocampal proteome database pub-
lished to date. We applied a hypothesis-driven set of
filtering criteria, based on protein’s cellular origin and
identification in the cerebrospinal fluid proteome to find
proteins that can be used as potential biomarkers in
cerebrospinal fluid.
Figure 3 Alzheimer’s disease pathway from the KEGG database. AD pathway (hsa05010) presents the up-regulated (marked in red) and
down regulated (marked in green) proteins identified in the current proteomic study. Proteins involved in beta-amyloid aggregation, calcium
signalling pathway and mitochondrial dysfunction are identified as significantly up-regulated by spectral counting methods.
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Post-mortem frozen brain hippocampal tissues were
obtained with Research Ethics Board approval from the
University Health Network, Toronto, Canada. Three
pathologically confirmed AD tissues (all three had Braak
stage 6/6) were obtained from three female patients
(aged 69, 75 and 98 years) with PMI of 13, 4 and 19.5
hours, respectively, while three control tissues were
obtained from one female (aged 77 years) and two male
patients (aged 78 and 80 years) with PMI of 12, 12 and 4
hours, respectively. Control patients were diagnosed
with non-metastatic colon cancer, cardiovascular disease
and heart failure, respectively. Prior to digestion, frozen
tissue sections from both AD and controls were cut and
weighted (~150 mg wet weight). Proteins from these six
brain tissues were extracted and solubilized using 0.2%RapiGest (Waters Corporation, Milford, USA) in 50 mM
ammonium bicarbonate. Briefly, tissue samples were ho-
mogenized (Polytron PT3100, Capitol Scientific, Austin,
USA) at 15,000 rpm, for 15 s and sonicated on ice three
times for 15 s with MISONIX immersion tip sonicator
(Q SONICA LLC, CT, USA). The samples were
centrifuged at 15,000 g at 4°C for 20 min; the superna-
tants were collected and measured for total protein con-
tent. Three AD tissues and three control tissues were
pooled separately and an equal amount (3 mg) of protein
from each pool was processed. Proteins were reduced
and alkylated with 5 mM dithiothreitol and 15 mM
iodoacetamide. To digest the proteins, sequencing grade
trypsin (Promega, WI, USA) was added, at an enzyme to
substrate ratio of 1:50 and the digestion was carried out
at 37°C for 18 hours. Fractionation of acidified tryptic-
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aspartamide strong cation exchange (SCX) column (2.1
mmID × 200 mm; 5 μ; 200 °A; The Nest Group, Inc.,
MA, USA) connected to an Agilent 1100 HPLC system.
SCX fractionation was performed in triplicate for AD
and control pools, and 20 fractions were collected per
chromatographic run. This amounted to a total of 120
SCX fractions, which were then subjected to LC-MS/MS
analysis after a brief desalting procedure. A 60 min lin-
ear gradient method was operated with buffer A→ B
(Buffer A: 0.26 M formic acid (FA) in 5% acetonitrile, B:
0.26 M FA in 5% acetonitrile and 1 M ammonium for-
mate) at a flow rate of 250 μL/min. SCX fractionation
was performed in triplicate for AD and control pools.
The peptides from SCX fractions were desalted and
injected onto a nano-LC system (Proxeon Biosystems,
Odense, Denmark) connected online to LTQ-Orbitrap
XL mass spectrometer (Thermo Fisher Scientific, San
Jose, CA, USA). A 90 min linear gradient reverse-phase
chromatography (Buffer A: 0.1% FA in water and B: 0.1%
FA in acetonitrile) at a flow rate of 400 nL/min was
performed to resolve peptides on a C18 column (75
μM× 5 cm). The mass spectra were acquired in data-
dependent mode. The MS spectra were searched against
the non-redundant IPI human database (version 3.71
containing both forward and reverse protein sequences)
using two search engines, separately: Mascot, version
2.1.03 (Matrix Science) and the Global Proteome
Machine manager, version 2006.06.01. The following
parameters were used: (I) enzyme: trypsin; (II) one
missed cleavage allowed; (III) fixed modification:
carbamidomethylation of cysteines; (IV) variable
modifications: oxidation of methionines; (V) MS1 tol-
erance, 7 ppm; and (VI) MS2 tolerance, 0.4 Da. The
resulting Mascot DAT and X! Tandem XML files
were merged using Scaffold® (version 2.06, Proteome
Software Inc., Portland, Oregon) with ‘MudPIT’
(multidimensional protein identification technology)
option checked. Scaffold data was filtered using the
X! Tandem Log E (min 3.0) and Mascot ion-score
filters [ion score 15, 30 (+2) and 40 (+3)] in order
to obtain a protein false-positive rate (FPR) of ≤ 1%.
FPR = 2 × (number of proteins identified by searching
the reverse sequences)/(the total number of identi-
fied proteins). Scaffold® protXML reports were
exported and uploaded into Protein Center (Proxeon
Biosystems, Odense, Denmark) to create Venn
diagrams.
The proteomic data associated with this manuscript
may be downloaded from ProteomeCommons.org Tra
nche using the following hash Khn5Yg/CHsUFAZFa
ObXXCrT75bIRXHdWuJLgEDPWwgT + A5+/62Ijmc4
Y/jhNS1GTXxORV7gfkaIbskPpU6RCbwIDDF4AAAAA
AAADIg==Encrypt passcode: ecPC48nIVr0iD6OzSDSaThe data can be viewed with Scaffold (ver. 2.6) viewer,
a freeware available on http://www.proteomesoftware.
com/Scaffold/Scaffold_viewer.htm.
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